ExpreS2ion announces financial results for the first quarter 2022
Hørsholm, Denmark, May 31, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “The quarter started on a strong note, as we were able to present further positive preclinical proof-of-concept results for our HER2-cVLP breast cancer vaccine in the beginning of January and positive proof-of-concept also in a metastatic outgrowth therapeutic tumor mice model here in May which